CoChat
Sign Up
Cited by 22Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersObsessive-Compulsive Spectrum Disorders

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Management of impulse control disorders in Parkinson's disease

Open access
Zhang, Susan, Dissanayaka, Nadeeka N., Dawson, Andrew, O'Sullivan, John D., Mosley, Philip, Hall, Wayne, Carter, Adrian·2016·International Psychogeriatrics
DOI 10.1017/s104161021600096x
Open this paper in CoChat — free account

Abstract

BACKGROUND: Impulse control disorders (ICDs) have become a widely recognized non-motor complication of Parkinson's disease (PD) in patients taking dopamine replacement therapy (DRT). There are no current evidence-based recommendations for their treatment, other than reducing their dopaminergic medication. METHODS: This study reviews the current literature of the treatment of ICDs including pharmacological treatments, deep brain stimulation, and psychotherapeutic interventions. RESULTS: Dopamine agonist withdrawal is the most common and effective treatment, but may lead to an aversive withdrawal syndrome or motor symptom degeneration in some individuals. There is insufficient evidence for all other pharmacological treatments in treating ICDs in PD, including amantadine, serotonin selective reuptake inhibitors, antipsychotics, anticonvulsants, and opioid antagonists (e.g. naltrexone). Large randomized control trials need to be performed before these drugs can be routinely used for the treatment of ICDs in PD. Deep brain stimulation remains equivocal because ICD symptoms resolve in some patients after surgery but may appear de novo in others. Cognitive behavioral therapy has been shown to improve ICD symptoms in the only published study, although further research is urgently needed. CONCLUSIONS: Further research will allow for the development of evidence-based guidelines for the management of ICDs in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s104161021600096x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 80

  1. Amami, 2014, Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up, Journal of Neurology, Neurosurgery & Psychiatry, 86, 562, 10.1136/jnnp-2013-307214 · DOI
  2. Armon, 1996, Reversible parkinsonism and cognitive impairment with chronic valproate use, Neurology, 47, 626, 10.1212/WNL.47.3.626 · DOI
  3. Ardouin, 2006, Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation, Movement Disorders : Official Journal of the Movement Disorder Society, 21, 1941, 10.1002/mds.21098 · DOI
  4. Ardouin, 2009, Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease, Revue Neurologique, 165, 845, 10.1016/j.neurol.2009.06.003 · DOI
  5. Barone, 2010, Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial, The Lancet Neurology, 9, 573, 10.1016/S1474-4422(10)70106-X · DOI · Paper page
  6. Bermejo, 2008, Topiramate in managing impulse control disorders in Parkinson's disease, Parkinsonism and Related Disorders, 14, 448, 10.1016/j.parkreldis.2007.11.008 · DOI
  7. Bermejo, 2010, Zonisamide in managing impulse control disorders in Parkinson's disease, Journal of Neurology, 257, 1682, 10.1007/s00415-010-5603-7 · DOI
  8. Bortolato, 2012, Finasteride attenuates pathological gambling in patients with Parkinson disease, Journal of Clinical Psychopharmacology, 32, 424, 10.1097/JCP.0b013e3182549c2a · DOI
  9. Broen, 2011, Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review, Parkinsonism and Related Disorders, 17, 413, 10.1016/j.parkreldis.2011.02.013 · DOI
  10. Cavanagh, 2011, Subthalamic nucleus stimulation reverses mediofrontal influence over decision threshold, Nature Neuroscience, 14, 1462, 10.1038/nn.2925 · DOI
  11. Connolly, 2012, Drug treatments for the neuropsychiatric complications of Parkinson's disease, Expert Review of Neurotherapeutics, 12, 1439, 10.1586/ern.12.142 · DOI
  12. Crosby, 2003, Amantadine for dyskinesia in Parkinson's disease, Cochrane Database of Systematic Reviews, 2, CD003467
  13. Dagher, 2009, Personality, addiction, dopamine: insights from Parkinson's disease, Neuron, 61, 502, 10.1016/j.neuron.2009.01.031 · DOI
  14. Delaney, 2012, Impulse control disorders in Parkinson's disease: a psychosocial perspective, Journal of Clinical Psychology in Medical Settings, 19, 338, 10.1007/s10880-012-9302-7 · DOI · Paper page
  15. Dodd, 2005, Pathological gambling caused by drugs used to treat Parkinson disease, Archives of Neurology, 62, 1377, 10.1001/archneur.62.9.noc50009 · DOI · Paper page
  16. Dreher, 2009, Chapter 19 - The basal ganglia in reward and decision making: computational models and empirical studies, 399
  17. Eusebio, 2013, Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease, Journal of Neurology, Neurosurgery, and Psychiatry, 84, 868, 10.1136/jnnp-2012-302387 · DOI
  18. Evans, 2004, Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome, Movement Disorders: Official Journal of the Movement Disorder Society, 19, 397, 10.1002/mds.20045 · DOI
  19. Fernandez, 1998, Clozapine for dopaminergic-induced paraphilias in Parkinson's disease, Movement Disorders: Official Journal of the Movement Disorder Society, 13, 597, 10.1002/mds.870130338 · DOI
  20. Frank, 2007, Hold your horses: impulsivity, deep brain stimulation, and medication in Parkinsonism, Science, 318, 1309, 10.1126/science.1146157 · DOI
  21. Gee, 2015, The influence of bilateral subthalamic nucleus deep brain stimulation on impulsivity and prepulse inhibition in Parkinson's disease patients, Stereotactic and Functional Neurosurgery, 93, 265, 10.1159/000381558 · DOI
  22. Gerlach, 2003, Dopamine receptor agonists in current clinical use: comparative receptor binding profiles defined in the human striatum, Journal of Neural Transmission, 110, 1119, 10.1007/s00702-003-0027-5 · DOI
  23. Grant, 2007, N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study, Biological Psychiatry, 62, 652, 10.1016/j.biopsych.2006.11.021 · DOI
  24. Grant, 2010, Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study, The British Journal of Psychiatry: The Journal of Mental Science, 197, 330, 10.1192/bjp.bp.110.078105 · DOI
  25. Green, 2013, Reduction of influence of task difficulty on perceptual decision making by STN deep brain stimulation, Current Biology, 23, 1681, 10.1016/j.cub.2013.07.001 · DOI
  26. Gurevich, 1999, Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons., Neuropsychopharmacology, 20, 60, 10.1016/S0893-133X(98)00066-9 · DOI
  27. Halbig, 2009, Subthalamic deep brain stimulation and impulse control in Parkinson's disease, European Journal of Neurology, 16, 493, 10.1111/j.1468-1331.2008.02509.x · DOI
  28. Hardwick, 2013, Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease, Neurocase, 19, 587, 10.1080/13554794.2012.713490 · DOI
  29. Haynes, 2013, The organization of prefrontal-subthalamic inputs in primates provides an anatomical substrate for both functional specificity and integration: implications for Basal Ganglia models and deep brain stimulation, Journal of Neuroscience, 33, 4804, 10.1523/JNEUROSCI.4674-12.2013 · DOI
  30. Hershey, 2004, Stimulation of STN impairs aspects of cognitive control in PD, Neurology, 62, 1110, 10.1212/01.WNL.0000118202.19098.10 · DOI
  31. Hicks, 2011, Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease, Parkinsonism & Related Disorders, 17, 379, 10.1016/j.parkreldis.2011.03.003 · DOI
  32. Hollander, 2000, A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling, Biological Psychiatry, 47, 813, 10.1016/S0006-3223(00)00241-9 · DOI
  33. Ivanco, 2005, Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study, American Journal of Therapeutics, 12, 467, 10.1097/01.mjt.0000151861.59698.26 · DOI
  34. Kehagia, 2014, Targeting impulsivity in Parkinson's disease using atomoxetine, Brain, 137, 1986, 10.1093/brain/awu117 · DOI
  35. Kurlan, 2004, Disabling repetitive behaviors in Parkinson's disease, Movement Disorders: Official Journal of the Movement Disorder Society, 19, 433, 10.1002/mds.10625 · DOI
  36. Lambert, 2012, Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging, Neuroimage, 60, 83, 10.1016/j.neuroimage.2011.11.082 · DOI
  37. Lee, 2011, Is pathological gambling in Parkinson's disease reduced by amantadine?, Annals of Neurology, 69, 213, 10.1002/ana.22289 · DOI
  38. Lhommee, 2012, Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours, Brain, 135, 1463, 10.1093/brain/aws078 · DOI
  39. Liang, 2015, Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study, Neurology, 84, 1386, 10.1212/WNL.0000000000001458 · DOI
  40. Lim, 2008, Impulse control and related disorders in Parkinson's disease: review, Annals of the New York Academy of Sciences, 1142, 85, 10.1196/annals.1444.006 · DOI
  41. Lim, 2009, Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease, Journal of Clinical Neuroscience, 16, 1148, 10.1016/j.jocn.2008.12.010 · DOI
  42. Lu, 2006, Gambling and Parkinson disease, Archives of Neurology, 63, 298, 10.1001/archneur.63.2.298-a · DOI
  43. Macphee, 2013, Managing impulse control behaviours in Parkinson's disease: practical guidelines, British Journal of Hospital Medicine, 74, 160, 10.12968/hmed.2013.74.3.160 · DOI
  44. Macphee, 2009, Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study, Movement Disorders : Official Journal of the Movement Disorder Society, 24, 2430, 10.1002/mds.22824 · DOI
  45. Mamikonyan, 2008, Long-term follow-up of impulse control disorders in Parkinson's disease, Movement Disorders : Official Journal of the Movement Disorder Society, 23, 75, 10.1002/mds.21770 · DOI
  46. McElroy, 1994, Compulsive buying: a report of 20 cases, Journal of Clinical Psychiatry, 55, 242
  47. Mestre, 2013, Diagnosis and treatment of impulse control disorders in patients with movement disorders, Therapeutic Advances in Neurological Disorders, 6, 175, 10.1177/1756285613476127 · DOI
  48. Moum, 2012, Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome, PLoS One, 7, e29768, 10.1371/journal.pone.0029768 · DOI
  49. Nirenberg, 2013, Dopamine agonist withdrawal syndrome: implications for patient care, Drugs & Aging, 30, 587, 10.1007/s40266-013-0090-z · DOI
  50. Nirenberg, 2006, Compulsive eating and weight gain related to dopamine agonist use, Movement Disorders : Official Journal of the Movement Disorder Society, 21, 524, 10.1002/mds.20757 · DOI
  51. Obeso, 2011, Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease, Experimental Brain Research, 212, 371, 10.1007/s00221-011-2736-6 · DOI
  52. Okai, 2015, Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson's disease, Movement Disorders: Official Journal of the Movement Disorder Society, 30, 736, 10.1002/mds.26108 · DOI
  53. Papay, 2014, Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study, Neurology, 83, 826, 10.1212/WNL.0000000000000729 · DOI
  54. Parkinson Study Group, 1997, Safety and efficacy of pramipexole in early Parkinson disease, JAMA, 278, 125, 10.1001/jama.1997.03550020057038 · DOI
  55. Rabinak, 2010, Dopamine agonist withdrawal syndrome in Parkinson disease, Archives of Neurology, 67, 58, 10.1001/archneurol.2009.294 · DOI
  56. Rotondo, 2010, Clozapine for medication-related pathological gambling in Parkinson disease, Movement Disorders : Official Journal of the Movement Disorder Society, 25, 1994, 10.1002/mds.23177 · DOI
  57. Ruggieri, 1997, Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease, Clinical Neuropharmacology, 20, 204, 10.1097/00002826-199706000-00003 · DOI
  58. Schneider, 2013, Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia, European Psychiatry: The Journal of the Association of European Psychiatrists, 29, 1
  59. Schreiber, 2011, Impulse control disorders: updated review of clinical characteristics and pharmacological management, Front Psychiatry, 2, 1, 10.3389/fpsyt.2011.00001 · DOI
  60. Schuepbach, 2013, Neurostimulation for Parkinson's disease with early motor complications, New England Journal of Medicine, 368, 610, 10.1056/NEJMoa1205158 · DOI
  61. Seppi, 2011, The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease, Movement Disorders: Official Journal of the Movement Disorder Society, 26, S42
  62. Sevincok, 2007, Quetiapine in a case with Parkinson disease and pathological gambling, Journal of Clinical Psychopharmacology, 27, 107, 10.1097/JCP.0b013e31802e98c3 · DOI
  63. Shotbolt, 2012, Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review, Parkinsonism & Related Disorders, 18, 10, 10.1016/j.parkreldis.2011.08.016 · DOI
  64. Silberstein, 2009, Deep brain stimulation for Parkinson's disease: Australian referral guidelines, Journal of Clinical Neuroscience, 16, 1001, 10.1016/j.jocn.2008.11.026 · DOI
  65. Smeding, 2007, Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease, Journal of Neurology Neurosurgery & Psychiatry, 78, 517, 10.1136/jnnp.2006.102061 · DOI
  66. Sokoloff, 1990, Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics., Nature, 347, 146, 10.1038/347146a0 · DOI
  67. Sohtaoglu, 2010, Long term follow-up of Parkinson's disease patients with impulse control disorders, Parkinsonism & Related Disorders, 16, 334, 10.1016/j.parkreldis.2010.02.006 · DOI
  68. Thibaut, 2010, The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of paraphilias, The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry, 11, 604, 10.3109/15622971003671628 · DOI · Paper page
  69. Thobois, 2007, STN stimulation alters pallidal-frontal coupling during response selection under competition, Journal of Cerebral Blood Flow and Metabolism, 27, 1173, 10.1038/sj.jcbfm.9600425 · DOI
  70. Thobois, 2010, Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation, Brain: A Journal of Neurology, 133, 1111, 10.1093/brain/awq032 · DOI
  71. Thomas, 2010, Pathological gambling in Parkinson disease is reduced by amantadine, Annals of Neurology, 68, 400, 10.1002/ana.22029 · DOI
  72. Trosch, 1998, Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience, Movement Disorders: Official Journal of the Movement Disorder Society, 13, 377, 10.1002/mds.870130302 · DOI
  73. Voon, 2006, Prevalence of repetitive and reward-seeking behaviors in Parkinson disease, Neurology, 67, 1254, 10.1212/01.wnl.0000238503.20816.13 · DOI
  74. Voon, 2007, Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease, Archives of Neurology, 64, 212, 10.1001/archneur.64.2.212 · DOI
  75. Voon, 2011, Impulse control disorders in Parkinson disease: a multicenter case control study, Annals of Neurology, 69, 986, 10.1002/ana.22356 · DOI
  76. Walsh, 2012, Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine, Movement Disorders: Official Journal of the Movement Disorder Society, 27, 326, 10.1002/mds.23964 · DOI
  77. Weintraub, 2008, Dopamine and impulse control disorders in Parkinson's disease, Annals of Neurology, 64, S93
  78. Weintraub, 2010, Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients, Archives of Neurology, 67, 589, 10.1001/archneurol.2010.65 · DOI
  79. Weintraub, 2010, Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study, Annals of Neurology, 68, 963, 10.1002/ana.22164 · DOI
  80. Witt, 2004, Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease, Archives of Neurology, 61, 697, 10.1001/archneur.61.5.697 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zhang, S., Dissanayaka, N. N., Dawson, A., O'Sullivan, J. D., Mosley, P., Hall, W., & Carter, A.
Affiliations
  • The University of Queensland (AU)
  • Monash University (AU)
Corresponding author
Carter, Adrian
ORCID
Venue
International Psychogeriatrics
Publisher
Elsevier BV
Published
2016-10
Volume
28
Issue
10
Pages
1597-1614
ISSN
1041-6102 (ISSN-L)
DOI
10.1017/s104161021600096x
OpenAlex
W2468704300
Cited by
22
References
3
Citations by year
2026: 3 · 2025: 2 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 2 · 2016: 1
FWCI
0.56
Type
journal article
Language
en
Open access
Licence
Locations
  • International Psychogeriatrics (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Australian Research Council (DE140101097)
  • Royal Brisbane and Women's Hospital Foundation
  • Lions Medical Research Foundation
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
Keywords
impulse control disorders, Parkinson's disease, dopamine replacement therapy, dopamine agonist withdrawal, deep brain stimulation, cognitive behavioral therapy, pharmacotherapy, selective serotonin reuptake inhibitors, antipsychotic drugs, naltrexone, amantadine, withdrawal syndrome
MeSH terms
Aged, Humans, Disruptive, Impulse Control, and Conduct Disorders, Parkinson Disease, Psychotropic Drugs, Cognitive Behavioral Therapy, Dopamine Agonists, Deep Brain Stimulation, Medication Therapy Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review